Equillium, Inc. announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono?s three-month option exercise period to acquire Equillium?s rights to itolizumab.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.801 USD | -10.69% | -46.60% | +10.79% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.79% | 28.24M | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.76% | 248B | |
-1.27% | 219B | |
+11.19% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease